LIPO — Lipella Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$1.85m
- $0.54m
Brief: Lipella Pharmaceuticals Inc. Files Voluntary Petitions For Relief Under Chapter 11
Brief: Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study Of LP-10 In Oral Lichen Planus
Brief: Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group
U.S. STOCKS ON THE MOVE-Biohaven, Ecolab, Firefly
U.S. STOCKS ON THE MOVE-Humana, S&P Global, Charles Schwab
U.S. STOCKS ON THE MOVE-Phillips 66, Coca-Cola, Leidos
Lipella jumps after inflammatory disease drug found safe in study
U.S. STOCKS ON THE MOVE-CC Holding, CBRE, Lexicon Pharmaceuticals
U.S. STOCKS ON THE MOVE-Jet.AI, SL Green, WTW
U.S. STOCKS ON THE MOVE-Tapestry, Eyenovia, Viking Therapeutics
Lipella rises after completing dosing of patient group in drug trial
Brief: Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310
Brief: Lipella Pharmaceuticals announces 1-for-8 reverse stock split
Brief: Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results In Phase 2A Trial Of Lp-310 For Oral Lichen Planus
Brief: Lipella Pharmaceuticals Got Notice Of Delisting From Nasdaq
Brief: Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Brief: Lipella Pharmaceuticals Expands Its Advisory Board To Include Oncology Expertise
Brief: Lipella Pharmaceuticals Announces FDA Type C Meeting For LP-10 For Hemorrhagic Cystitis